COVID vaccine by Serum completes enrollment for Phase-3 trials
The Serum Institute of India (SI) and ICMR on Thursday declared the completion of the enrolment process of 1,600 participants in the Phase – 3 clinical trials for the COVID-19 vaccine (Covishield) in India.
Serum Institute has completed the enrolment of all 1,600 participants on October 31.
The Institute and ICMR are now collaborating on the clinical trials of the vaccine.
The Oxford covid vaccine is currently being tested in large efficacy trials in the UK, Brazil, South Africa and the US. “The promising results of the trials so far give confidence that Covishield could be a realistic solution to the deadly pandemic,” Serum Institute said.
Currently, SII and the ICMR are conducting the Phase-2 and Phase-3 clinical trial of the vaccine at 15 various centers, the SII informed.
SII CEO Adar Poonawalla said, “ICMR has played a huge role in coming forward and strengthening India’s fight against COVID-19. The collaboration will further aid us in putting India at the forefront of developing an immunogenic and efficacious vaccine.”
The partnership further testifies the importance of private-public institutes collaborating in scaling up the management and containing the spread of Coronavirus, he further added.
ICMR Director General Balram Bhargava said that the partnership is their contribution to lending the expertise and support to fight against the global pandemic.
Earlier this week, Pfizer said its COVID-19 vaccine was more than 90% effective based on interim trial results, significantly higher than the at least 50% efficacy regulators are looking for.
Furthermore, US-based Novavax has initiated its late phase trials in South Africa and in the UK and will soon commence the same in the USA.
To support our brand of fearless and investigative journalism, support us HERE.
The Inside Northeast app HERE for News, Views, and Reviews from Northeast India.
Do keep following us for news on-the-go. We deliver the Northeast.